Table 2.
Various MOF-based phototherapeutic agents for cancer therapy
| Phototherapeutic agents | Photosensitizers (PSs) | Light source | Therapeutic agents | Applications | Refs. |
|---|---|---|---|---|---|
| Zr-PDI | Perylenediimide (PDI) | NIR | Zr-PDI*− | PTT | [111] |
| ZnO-CNP-TRGL | ZnO-CNP | NIR | Carbon nanoparticle | PTT | [112] |
| MOF@HA@ICG | Indocyanine green (ICG) | NIR | Hyaluronic acid (HA) | PTT | [94] |
| MIL-100@ ABTS | 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) | NIR | ·OH | PTT | [113] |
| Au@ZIF-8 | Au | NIR | DOX | NIR-II PTT and IR/PAI imaging | [114] |
| CuS@Fe-MOF | CuS | NIR | DOX | PTT | [115] |
| Hf6(μ3-O)4(μ3-OH)4(DBP)6 | Porphyrin DBP | Visible light | 1O2 | PDT | [119] |
| Hf6(μ3-O)4(μ3-OH)4(DBP)6 | Porphyrin DBC | Visible light | 1O2 | PDT | [120] |
| FA@PCN-224 | FA | Visible light | 1O2 | PDT | [121] |
| UCNP@PCN-224 | UCNPs | NIR | Tirapazamine (TPZ) and 1O2 | PDT and Chemotherapy | [124] |
| PCN-224-Pt | Porphyrin | NIR | 1O2 | PDT | [125] |
| BODIPY@ UiO-66 | BODIPY | NIR | 1O2 | PDT | [126] |
| Zn-TCPP-BPDTE | Porphyrin and dithienylethene (DTE) derivative | UV | 1O2 | PDT | [127] |
| UCNPs/MB@ZIF-8@catalase | UCNPs and Methylene blue | NIR | 1O2 | PDT | [128] |
| oxABTS@MIL-100 | Visible light | ·OH | CDT | [113] | |
| Cu-TBP | Tetracarboxyphenylporphyrin (H4TBP) | Visible light | ·OH and 1O2 | PDT and CDT | [135] |
| O2-Cu/ZIF-8@Ce6/ZIF-8@F127, | Ce6 | Visible light | ·OH and 1O2 | PDT and CDT | [136] |
| 99mTc-Hf-TCPP-PEG | Hf4+ and 99mTc | X-ray | ROS | RDT | [139] |
|
Hf6-DBA Hf12-DBA |
Hf4+ | X-ray | ROS | RDT | [140] |
| Zr-MOF-QU |
Zr4+ 1,4-benzenedicarboxylic acid |
X-ray | ROS | RDT | [142] |
| d-Arg-MIL-100 (Fe) | Fe3+ | X-ray | ·OH and 1O2 | RDT and CDT | [143] |